Stem Cell Research Commission Awards MSCRF $14 Million to Accelerate Cures By Alex KeownMay 24, 2023 The Maryland Stem Cell Research Commission, a division of TEDCO, handed out more than [….]
Caring Cross’ Boro Dropulić Shares His Vision for Affordable Cell and Gene Therapies By Alex KeownMay 2, 2023 Boro Dropulić, cofounder and executive director of Caring Cross shared his vision [….]
Based in Gaithersburg, Vector BioMed is the first B Corp to be spun out of Caring Cross, a non-profit organization dedicated to accelerating the development of advanced medicines and enabling access to cures for all patients. Caring Cross is developing cell therapy treatments for HIV and other diseases, including various oncology indications and the blood disorders sickle cell disease and beta-thalassemia. The organization intends to develop cost-effective therapies that will be passed along to patients. Dropulić is Executive Director of Caring Cross and will serve as Chief Executive Officer of the newly-established Vector BioMed.
No Patient Left Behind: Non-Profit Caring Cross Hopes to Create Affordable Cell Therapies With a mission of leaving no patient behind, Caring Cross is developing cell therapy treatments for HIV [….]
Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to cures for all patients, everywhere, announced the dosing of the first participant in a Phase 1/2a clinical trial evaluating the organization’s Anti-HIV DuoCAR-T cell therapy. Caring Cross has designed its Anti-HIV DuoCAR-T cell therapy to potentially eliminate HIV-infected cells and suppresses HIV infection long-term in the body after a single infusion.
Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to cures for all patients, everywhere, announced that Kim Anthony-Gonda, Ph.D., Director of Infectious Diseases at Caring Cross, presented a poster highlighting the organization’s Anti-HIV DuoCAR-T Cell Therapy at the Conference on Retroviruses and Opportunistic Infections (CROI) 2022.
